drugset / Trial / NCT03597217

A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults

NCT03597217

Phase 1 Completed 15 enrolled Pfizer
RandomizedCrossoverTriple-blindBasic science

Summary

The current study is designed to evaluate the safety, tolerability and pharmacokinetics of PF-05221304 in healthy Japanese adult subjects following single and multiple dose administration.

Timeline

Start
2018-08-27
Primary completion
2018-11-15
Completion
2018-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Clesacostat Small molecule 3 mg
Subject Clesacostat Small molecule 10 mg
Subject Clesacostat Small molecule 50 mg

Indications

No indication recorded.